These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36201269)

  • 1. Nanoparticle-based CRISPR/Cas Delivery: An Emerging Tactic for Cancer Therapy.
    Dilnawaz F; Acharya S
    Curr Med Chem; 2023; 30(31):3562-3581. PubMed ID: 36201269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The delivery challenge: fulfilling the promise of therapeutic genome editing.
    van Haasteren J; Li J; Scheideler OJ; Murthy N; Schaffer DV
    Nat Biotechnol; 2020 Jul; 38(7):845-855. PubMed ID: 32601435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
    Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
    J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas gene editing and delivery systems for cancer therapy.
    Li Y; Zhou S; Wu Q; Gong C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1938. PubMed ID: 38456346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment.
    Yang X; Zhang B
    Funct Integr Genomics; 2023 May; 23(2):182. PubMed ID: 37231285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
    Qiu M; Glass Z; Xu Q
    Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
    Tang H; Zhao X; Jiang X
    Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors.
    Xie R; Wang Y; Gong S
    Biomater Sci; 2021 Sep; 9(18):6012-6022. PubMed ID: 34286726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
    Cai W; Luo T; Mao L; Wang M
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
    Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
    Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
    Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
    Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.